The β-carbonic anhydrases from Mycobacterium tuberculosis as drug targets

Current Pharmaceutical Design

Volumn 16, Issue 29, 2010, Pages 3300-3309

  Nishimori, Isao ^a   Minakuchi, Tomoko ^a   Maresca, Alfonso ^b   Carta, Fabrizio ^b   Scozzafava, Andrea ^b   Supuran, Claudiu T ^b  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antituberculosis agents; Beta class enzyme; Carbonic anhydrase; Mycobacterium tuberculosis; Sulfonamide

Indexed keywords

ACETAZOLAMIDE; AMINO ACID; BENZOLAMIDE; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CELECOXIB; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; INDISULAM; METHAZOLAMIDE; MYCOLIC ACID; POLYPEPTIDE; SACCHARIN; SULFONAMIDE; SULPIRIDE; SULTIAME; TOPIRAMATE; VALDECOXIB; ZONISAMIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CATALYSIS; CLONING; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HYDRATION; IN VIVO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; ISOENZYMES; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONIC ACIDS;

EID: 78649878939     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793429814     Document Type: Article

References (39)

1. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-7.
2. Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008; 29: 552-9.
3. Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb) 2008; 88 (Suppl 1): S3-17.
4. Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in anti-tubeculous drug development and novel drug targets. Expert Rev Resp Med 2008; 2: 455-71.
5. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
6. Suarez Covarrubias A, Larsson AM, Hogbom M, et al. Structure and function of carbonic anhydrases from mycobacterium tuberculosis. J Biol Chem 2005; 280: 18782-9.
7. Suarez Covarrubias A, Bergfors T, Jones TA, Hogbom M. Structural mechanics of the pH-dependent activity of the β-carbonic anhydrase from mycobacterium tuberculosis. J Biol Chem 2006; 281: 4993-9.
8. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81.
9. Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008; 14: 641-8.
10. Supuran CT. Scozzafava A, Conway J, Eds. Carbonic anhydrase - Its inhibitors and activators. Boca Raton, New York, London: CRC Press 2004; pp. 1-363.
11. Nishimori I, Minakuchi T, Kohsaki T, et al. Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett 2007; 17: 3585-94.
12. Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alphacarbonic anhydrase from helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem 2006; 49: 2117-26.
13. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The α- and β- classes carbonic anhydrases from helicobacter pylori as novel drug targets. Curr Pharm Des 2008; 14: 622-30.
14. 2 sensing with cAMP signaling and virulence. Curr Biol 2005; 15: 2021-6.
15. Innocenti A, Mühlschlegel FA, Hall RA, Steegborn C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens candida albicans and cryptococcus neoformans with simple anions. Bioorg Med Chem Lett 2008; 18: 5066-70.
16. Innocenti A, Hall RA, Schlicker C, Mühlschlegel FA, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens candida albicans and cryptococcus neoformans with aliphatic and aromatic carboxylates. Bioorg Med Chem 2009; 17: 2654-7.
17. Isik S, Kockar F, Aydin M, et al. Carbonic anhydrase inhibitors. Inhibition of the β-class enzyme from the yeast saccharomyces cerevisiae with sulfonamides and sulfamates. Bioorg Med Chem 2009; 17: 1158-63.
18. Isik S, Kockar F, Aydin M, et al. Carbonic anhydrase inhibitors. Inhibition of the β-class enzyme from the yeast Saccharomyces cerevisiae with anions. Bioorg Med Chem Lett 2008; 18: 6327-31.
19. Strop P, Smith KS, Iverson TM, Ferry JG, Rees DC. Crystal structure of the cab-type β-class carbonic anhydrase from the archaeon methanobacterium thermoautotrophicum. J Biol Chem 2001; 276: 10299-305
20. Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal β-class (Cab) and γ-class (Cam) carbonic anhydrases. Curr Top Med Chem 2007; 7: 901-8.
21. Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors. Cloning, characterization and inhibition studies of a new β-carbonic anhydrase from mycobacterium tuberculosis. J Med Chem 2009; 52(9): 3116-20.
22. Minakuchi T, Nishimori I, Vullo D, Scozzafava A, Supuran CT. J Med Chem 2009; Molecular cloning, characterization and inhibition studies of the Rv1284 β-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J Med Chem 2009; 52: 2226-32.
23. Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, Supuran CT. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β-carbonic anhydrase from mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009; 19: 6649-54.
24. Maresca A, Carta F, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 β- carbonic anhydrases from mycobacterium tuberculosis with diazenylbenzenesulfonamides. Bioorg Med Chem Lett 2009; 19: 4929-32.
25. Güzel O, Maresca A, Scozzafava A, Salman A, Balaban AT, Supuran CT. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial β-carbonic anhydrases Rv1284 and Rv3273. J Med Chem 2009; 52: 4063-7.
26. 2-sensing carbonic anhydrase can2 from the pathogenic fungus cryptococcus neoformans. J Mol Biol 2009; 385: 1207-20.
27. Smith KS, Ferry JG. A plant-type (beta-class) carbonic anhydrase in the thermophilic methanoarchaeon methanobacterium thermoautotrophicum. J Bacteriol 1999; 181: 6247-53.
28. Smith KS, Cosper NJ, Stalhandske C, Scott RA, Ferry JG. Structural and kinetic characterization of an archaeal β-class carbonic anhydrase. J Bacteriol 2000; 182: 6605-13.
29. Smith KS, Ingram-Smith C, Ferry JG. Roles of the conserved aspartate and arginine in the catalytic mechanism of an archaeal ßclass carbonic anhydrase. J Bacteriol 2002; 184: 4240-5.
30. Cronk JD, Endrizzi JA, Cronk MR, O'Neill JW, Zhang KY. Crystal structure of E. coli β-carbonic anhydrase, an enzyme with an unusual pH-dependent activity. Protein Sci 2001; 10: 911-22.
31. Cronk JD, Rowlett RS, Zhang KY, et al. Identification of a novel noncatalytic bicarbonate binding site in eubacterial β-carbonic anhydrase. Biochemistry 2006; 45: 4351-4361.
32. 2 hydration. J Biol Chem 2000; 275: 5521-6.
33. Joseph P, Turtaut F, Ouahrani-Bettache S, et al. Cloning, characterization and inhibition studies of a β-carbonic anhydrase from brucella suis. J Med Chem 2010; 53: 2277-85.
34. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003; 48: 77-84.
35. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43: 717-31.
36. Miltner E, Daroogheh K, Mehta PK, Cirillo SL, Cirillo JD, Bermudez LE. Identification of mycobacterium avium genes that affect invasion of the intestinal epithelium. Infect Immun 2005; 73: 4214-21.
37. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008; 14(7): 622-630.
38. Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008; 14(7): 641-648.
39. Supuran CT. Carbonic anhydrases--an overview. Curr Pharm Des 2008; 14(7): 603-614.